# Evaluating ER-100 for Safety in People With Glaucoma or Non-Arteritic Anterior Ischemic Optic Neuropathy (Optic Nerve Conditions)

> **NCT07290244** · PHASE1 · RECRUITING · sponsor: **Life Biosciences Inc.** · enrollment: 18 (estimated)

## Conditions studied

- Open Angle Glaucoma (OAG)
- NAION( Non-arteritic Anterior Ischemic Optic Neuropathy)

## Interventions

- **GENETIC:** ER-100 epigenetic therapy

## Key facts

- **NCT ID:** NCT07290244
- **Lead sponsor:** Life Biosciences Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-02
- **Primary completion:** 2027-05
- **Final completion:** 2032-03
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2026-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07290244

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07290244, "Evaluating ER-100 for Safety in People With Glaucoma or Non-Arteritic Anterior Ischemic Optic Neuropathy (Optic Nerve Conditions)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07290244. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*